公开(公告)号：US11433061B2

公开(公告)日：2022-09-06

申请号：US16739204

申请日：2020-01-10

申请人： ChemoCentryx, Inc.

发明人： Solomon Ungashe ,  Zheng Wei ,  Arindrajit Basak ,  Trevor T. Charvat ,  Wei Chen ,  Jeff Jin ,  Jimmie Moore ,  Yibin Zeng ,  Sreenivas Punna ,  Daniel Dairaghi ,  Derek Hansen ,  Andrew M. K. Pennell ,  John J. Wright ,  Antoni Krasinski ,  Qiang Wang

IPC分类号： A61K31/444 ,  C07C311/21 ,  C07D213/75 ,  C07D241/22 ,  C07D401/06 ,  C07D401/10 ,  C07D407/04 ,  C07D409/12 ,  C07D413/06 ,  C07D417/12 ,  C07D471/04 ,  C07D498/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K45/06

摘要： Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

公开(公告)号：US20160296517A1

公开(公告)日：2016-10-13

申请号：US15050691

申请日：2016-02-23

申请人： CHEMOCENTRYX, INC.

发明人： Penglie ZHANG ,  Andrew M. K. Pennell ,  John J. Kim Wright ,  Wei Chen ,  Manmohan R. Leleti ,  Yandong Li ,  Lianfa Li ,  Yuan Xu ,  Mark M. Gleason ,  Yibin Zeng ,  Kevin Lloyd Greenman

IPC分类号： A61K31/496 ,  A61K31/5377 ,  A61K45/06

CPC分类号： A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04

摘要： Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

公开(公告)号：US10532044B2

公开(公告)日：2020-01-14

申请号：US16272401

申请日：2019-02-11

申请人： ChemoCentryx, Inc.

发明人： Solomon Ungashe ,  Zheng Wei ,  Arindrajit Basak ,  Trevor T. Charvat ,  Wei Chen ,  Jeff Jin ,  Jimmie Moore ,  Yibin Zeng ,  Sreenivas Punna ,  Daniel Dairaghi ,  Derek Hansen ,  Andrew M. K. Pennell ,  John J. Wright ,  Antoni Krasinski ,  Qiang Wang

IPC分类号： A61K31/444 ,  C07C311/21 ,  C07D213/75 ,  C07D241/22 ,  C07D401/06 ,  C07D401/10 ,  C07D407/04 ,  C07D409/12 ,  C07D413/06 ,  C07D417/12 ,  C07D471/04 ,  C07D498/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K45/06

摘要： Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

公开(公告)号：US10206912B2

公开(公告)日：2019-02-19

申请号：US15383788

申请日：2016-12-19

申请人： ChemoCentryx, Inc.

发明人： Solomon Ungashe ,  Zheng Wei ,  Arindrajit Basak ,  Trevor T. Charvat ,  Wei Chen ,  Jeff Jin ,  Jimmie Moore ,  Yibin Zeng ,  Sreenivas Punna ,  Daniel Dairaghi ,  Derek Hansen ,  Andrew M. K. Pennell ,  John J. Wright ,  Antoni Krasinski ,  Qiang Wang

IPC分类号： C07C311/21 ,  A61K31/444 ,  C07D213/75 ,  C07D241/22 ,  C07D401/06 ,  C07D401/10 ,  C07D407/04 ,  C07D409/12 ,  C07D413/06 ,  C07D417/12 ,  C07D471/04 ,  C07D498/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K45/06

摘要： Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

公开(公告)号：US09409909B2

公开(公告)日：2016-08-09

申请号：US14446127

申请日：2014-07-29

申请人： ChemoCentryx, Inc.

发明人： Trevor T. Charvat ,  Cheng Hu ,  Anita Melikian ,  Aaron Novack ,  Andrew M. K. Pennell ,  Edward J. Sullivan ,  William D. Thomas ,  Solomon Ungashe ,  Penglie Zhang ,  Jay Powers ,  Sreenivas Punna

IPC分类号： C07D213/02 ,  C07D473/00 ,  C07D209/08 ,  C07D231/12 ,  C07D231/14 ,  C07D231/16 ,  C07D231/56 ,  C07D233/61 ,  C07D235/06 ,  C07D235/08 ,  C07D249/06 ,  C07D249/18 ,  C07D401/04 ,  C07D401/14 ,  C07D403/06 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4192 ,  A61K31/437 ,  A61K31/496 ,  A61K31/52 ,  A61K31/5377 ,  A61K45/06

CPC分类号： C07D473/00 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4192 ,  A61K31/437 ,  A61K31/496 ,  A61K31/52 ,  A61K31/5377 ,  A61K45/06 ,  C07D209/08 ,  C07D231/12 ,  C07D231/14 ,  C07D231/16 ,  C07D231/56 ,  C07D233/61 ,  C07D235/06 ,  C07D235/08 ,  C07D249/06 ,  C07D249/18 ,  C07D401/04 ,  C07D401/14 ,  C07D403/06 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C12N2501/999

摘要： Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

摘要翻译： 提供了作为CCR9受体的有效拮抗剂的化合物。 动物实验表明，这些化合物可用于治疗炎症，CCR9的特征性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR9介导的疾病的方法，以及用于鉴定CCR9拮抗剂的测定中的对照。

公开(公告)号：US09296740B2

公开(公告)日：2016-03-29

申请号：US13774938

申请日：2013-02-22

申请人： ChemoCentryx, Inc.

发明人： Penglie Zhang ,  Andrew M. K. Pennell ,  John J. Kim Wright ,  Wei Chen ,  Manmohan R. Leleti ,  Yandong Li ,  Lianfa Li ,  Yuan Xu ,  Mark M. Gleason ,  Yibin Zeng ,  Kevin Lloyd Greenman

IPC分类号： C07D471/04 ,  C07D487/04

CPC分类号： A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04

摘要： Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.